Journal of Medical Diagnostic Methods
Open Access

Takuji Okusaka

Publications

• Research Article
  Multicenter, Open-Label, Phase I/II Study of Tocilizumab, an Anti–Interleukin-6 Receptor Monoclonal Antibody, Combined with Gemcitabine in Patients with Advanced Pancreatic Cancer
  Author(s): Mitsunaga S, Okusaka T, Ikeda M, Ozaka M, Ohkawa S, et al. Mitsunaga S, Okusaka T, Ikeda M, Ozaka M, Ohkawa S, et al.
  
  Background: To assess the efficacy, safety and pharmacokinetics of tocilizumab + gemcitabine in patients with advanced pancreatic cancer. Methods: Patients with treatment-naive advanced pancreatic cancer and high inflammatory burden (C-reactive protein ≥ 2 mg/dl) without obvious infections received tocilizumab (8 mg/kg) intravenously every 2 weeks with intravenous gemcitabine (1,000 mg/m2) on days 1, 8 and 15 of each 4-week cycle until disease progression or study withdrawal. Interleukin-6 signalling inhibition biomarkers were measured. Efficacy analyses included overall survival, progression-free survival, tumour response and clinical symptoms. Adverse events and laboratory parameters were also assessed. Results: Fifteen patients received tocilizumab+gemcitabine. Tumour response was observed in two patients (13.. View More»
  DOI: 10.4172/2168-9784.1000234

  Abstract PDF

Relevant Topics